Scarica l'app Stockscreener
1.42
2.07%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.45
Aprire:
$1.47
Volume 24 ore:
78,981
Relative Volume:
0.80
Capitalizzazione di mercato:
$69.89M
Reddito:
$596.60K
Utile/perdita netta:
$-11.72M
Rapporto P/E:
-5.9514
EPS:
-0.2386
Flusso di cassa netto:
$-9.51M
1 W Prestazione:
-6.58%
1M Prestazione:
-43.65%
6M Prestazione:
-1.39%
1 anno Prestazione:
+13.60%
Intervallo 1D:
$1.42
$1.4988
Intervallo di 1 settimana:
$1.42
$1.575
Portata 52W:
$1.168
$3.8999
Medicinova Inc Stock (MNOV) Company Profile
Nome
Medicinova Inc
Settore
Industria
Telefono
858-373-1500
Indirizzo
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.42 | 69.89M | 596.60K | -11.72M | -9.51M | -0.2386 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-17 | Iniziato | Roth Capital | Buy |
| 2026-03-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-10 | Iniziato | Maxim Group | Buy |
| 2019-03-25 | Ripresa | B. Riley FBR | Buy |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | Iniziato | Credit Suisse | Outperform |
| 2013-01-04 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-05-24 | Downgrade | MLV & Co | Buy → Hold |
| 2011-10-18 | Reiterato | MLV Capital | Buy |
| 2011-06-22 | Iniziato | Global Hunter Securities | Buy |
| 2010-05-12 | Iniziato | Wedbush | Outperform |
| 2008-11-12 | Reiterato | Ladenburg Thalmann | Buy |
| 2008-05-15 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | Iniziato | Punk, Ziegel & Co | Buy |
Mostra tutto
Medicinova Inc Borsa (MNOV) Ultime notizie
MediciNova reports mixed MN-001 results. Analysts give MediciNova stock a Moderate Buy rating - ad-hoc-news.de
MediciNova, Inc. (MNOV) Stock Price, News, Quote & History - Yahoo! Finance Canada
MediciNova’s MN-001 trial misses primary endpoints in NAFLD By Investing.com - Investing.com Nigeria
MediciNova’s MN-001 trial misses primary endpoints in NAFLD By Investing.com - Investing.com South Africa
MediciNova CEO Provides Shareholder Update - GlobeNewswire Inc.
MediciNova CEO Provides Shareholder Update - GlobeNewswire
Two cholesterol measures improved significantly, but the trial missed its primary endpoints. - Stock Titan
Issuance/retirement of debt (net) of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova Company Profile & Introduction - Moomoo
MediciNova to Participate in the Maxim Growth Summit - Yahoo Finance Australia
MediciNova to Participate in the Maxim Growth Summit - GlobeNewswire Inc.
MediciNova to Participate in the Maxim Growth Summit - Yahoo Finance
MediciNova to Participate in the Maxim Growth Summit - GlobeNewswire
MediciNova (4875) Stock Forum and Discussion - Moomoo
MediciNova stock gained 9.20 percent after mixed Phase 2 data - AD HOC NEWS
MediciNova Company Profile & Introduction - Moomoo
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
3D Investment Partners Updates MediciNova Holdings, Reports Private Sale and Swap Agreements - Kalkine Media
Two holders sold 640,000 MediciNova (NASDAQ: MNOV) shares and still report an ownership stake. - Stock Titan
After a sale, an investment manager still reports 4.86 million MediciNova (MNOV) shares held indirectly. - Stock Titan
H.C. Wainwright reiterates Buy on MediciNova stock, $10 target - Investing.com
MediciNova (NasdaqGM:MNOV) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com Nigeria
MediciNova extends office lease to 2030 and agrees to rent increases By Investing.com - Investing.com Nigeria
MediciNova extends office lease to 2030 and agrees to rent increases - Investing.com
MediciNova extends office lease to 2030 and agrees to rent increases By Investing.com - Investing.com Australia
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com South Africa
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com India
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com Canada
Form 8K MediciNova Inc For: 28 September By Investing.com - Investing.com UK
Rent increases take effect in February 2027 under MediciNova's (MNOV) amended lease. - Stock Titan
Why Is MediciNova Stock Tumbling Today?MediciNova (NASDAQ:MNOV) - Benzinga
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints - Yahoo Finance
Why is MediciNova stock sliding today? By Investing.com - Investing.com South Africa
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data - Yahoo Finance
Why is MediciNova stock sliding today? - Investing.com
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data - Investing.com
MediciNova reports mixed phase 2 results for MN-001 drug trial - Investing.com Nigeria
MediciNova misses both Phase 2 endpoints despite HDL gains - Mugglehead Investment Magazine
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewswire Inc.
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewswire
A 40-person study found more “good” cholesterol with MediciNova's drug, but no significant liver-fat difference. - Stock Titan
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles - Yahoo Finance
MediciNova completes double-blind phase of ALS drug trial By Investing.com - Investing.com Canada
MediciNova completes double-blind phase of ALS drug trial - Investing.com
MediciNova completes double-blind phase of ALS drug trial By Investing.com - Investing.com Nigeria
MediciNova Announces Last Patient, Last Visit in Double-Blind Portion of COMBAT-ALS Phase 2b/3 Trial of MN-166 for ALS - Quiver Quantitative
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) - Yahoo Finance Singapore
The blinded phase of an ALS drug trial is complete. Results are expected by year-end. - Stock Titan
MediciNova Announces Completion of Last Patient, Last Visit - GlobeNewswire
Medicinova Inc Azioni (MNOV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):